Items Tagged ‘paclitaxel’

September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


April 30th, 2015

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer

By

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released online by the journal The Lancet. Node-positive breast cancer means that cancer cells from the breast have been found in the lymph nodes under the arm. Although […]

View full entry

Tags: Breast Cancer, cyclophosphamide, Cytoxan, early-stage, Ellence, epirubicin, fluorouracil, News, node-positive, paclitaxel, Stages II-III Breast Cancer, Taxol


April 29th, 2015

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer

By

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago, Illinois. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more […]

View full entry

Tags: avastin, bevacizumab, carboplatin, clinical trial, News, Ovarian Cancer, paclitaxel, platinum sensitive, Taxol


March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

By

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the […]

View full entry

Tags: Bladder Cancer, News, paclitaxel, pazopanib, Phase II study, Recurrent Bladder Cancer, Stages II-III Bladder Cancer, Taxol, Votrient


February 5th, 2015

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer

By

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings were presented at the 2014 San Antonio Breast Cancer Symposium, December 9–13, in San Antonio, Texas. Afinitor is an oral medication that works by inhibiting a protein known as mTOR. […]

View full entry

Tags: afinitor, Breast Cancer, herceptin, paclitaxel


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer